Recently, several novel anti-cytokine therapies, such as anti-IL-6 receptor antibodies and anti-IFN-γ antibodies, have achieved success in hemophagocytic lymphohistiocytosis and CAR-T-cell therapy-induced CSS (Fajgenbaum and June 2020). This evidence concerns the gene IFNG and hemophagocytic syndrome.